Stock Track | Innovent Biologics Soars 5% as New Lung Cancer Drug Limertinib Gets China Approval

Stock Track

Jan 17, 2025

Hong Kong-listed biotech firm Innovent Biologics (1801.HK) saw its shares soar 5.17% in intraday trading on Friday, following news that its third-generation EGFR TKI drug Limertinib received approval from China's medical regulator NMPA for treatment of a certain mutation in non-small cell lung cancer.

Limertinib targets the EGFR T790M mutation, which is present in up to 50% of Asian lung cancer patients with locally advanced or metastatic non-small cell lung cancer. This regulatory milestone clears the way for Innovent to market the drug and potentially opens up a significant revenue stream for the biotech firm.

The approval boosts Innovent's oncology drug pipeline and is a major win as it seeks to expand its portfolio of marketed products beyond its existing PD-1 antibody Tyvyt. Investors cheered the development, betting that Limertinib can become a blockbuster therapy given the high prevalence of the targetted mutation in Asian patient populations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1155965391"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155965391\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155965391?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-17 13:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155965391","market":"hk","top_or_hot":-1,"title":"Stock Track | Innovent Biologics Soars 5% as New Lung Cancer Drug Limertinib Gets China Approval","media":"Stock Track","content":"<p>Hong Kong-listed biotech firm Innovent Biologics (1801.HK) saw its shares soar 5.17% in intraday trading on Friday, following news that its third-generation EGFR TKI drug Limertinib received approval from China's medical regulator NMPA for treatment of a certain mutation in non-small cell lung cancer.</p>\n\n<p>Limertinib targets the EGFR T790M mutation, which is present in up to 50% of Asian lung cancer patients with locally advanced or metastatic non-small cell lung cancer. This regulatory milestone clears the way for Innovent to market the drug and potentially opens up a significant revenue stream for the biotech firm.</p>\n\n<p>The approval boosts Innovent's oncology drug pipeline and is a major win as it seeks to expand its portfolio of marketed products beyond its existing PD-1 antibody Tyvyt. Investors cheered the development, betting that Limertinib can become a blockbuster therapy given the high prevalence of the targetted mutation in Asian patient populations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Innovent Biologics Soars 5% as New Lung Cancer Drug Limertinib Gets China Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Innovent Biologics Soars 5% as New Lung Cancer Drug Limertinib Gets China Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-17 13:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed biotech firm Innovent Biologics (1801.HK) saw its shares soar 5.17% in intraday trading on Friday, following news that its third-generation EGFR TKI drug Limertinib received approval from China's medical regulator NMPA for treatment of a certain mutation in non-small cell lung cancer.</p>\n\n<p>Limertinib targets the EGFR T790M mutation, which is present in up to 50% of Asian lung cancer patients with locally advanced or metastatic non-small cell lung cancer. This regulatory milestone clears the way for Innovent to market the drug and potentially opens up a significant revenue stream for the biotech firm.</p>\n\n<p>The approval boosts Innovent's oncology drug pipeline and is a major win as it seeks to expand its portfolio of marketed products beyond its existing PD-1 antibody Tyvyt. Investors cheered the development, betting that Limertinib can become a blockbuster therapy given the high prevalence of the targetted mutation in Asian patient populations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1155965391","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155965391","pubTimestamp":1737091615,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hong Kong-listed biotech firm Innovent Biologics  saw its shares soar 5.17% in intraday trading on Friday, following news that its third-generation EGFR TKI drug Limertinib received approval from China's medical regulator NMPA for treatment of a certain mutation in non-small cell lung cancer.Limertinib targets the EGFR T790M mutation, which is present in up to 50% of Asian lung cancer patients with locally advanced or metastatic non-small cell lung cancer. This regulatory milestone clears the wa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"股票赛道信达生物飙升5%肺癌新药利美替尼获中国批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"Hong Kong-listed biotech firm Innovent Biologics (1801.HK) saw its shares soar 5.17% in intraday trading on Friday, following news that its third-generation EGFR TKI drug Limertinib received approval from China's medical regulator NMPA for treatment of a certain mutation in non-small cell lung cancer.\nLimertinib targets the EGFR T790M mutation, which is present in up to 50% of Asian lung cancer patients with locally advanced or metastatic non-small cell lung cancer. This regulatory milestone clears the way for Innovent to market the drug and potentially opens up a significant revenue stream for the biotech firm.\nThe approval boosts Innovent's oncology drug pipeline and is a major win as it seeks to expand its portfolio of marketed products beyond its existing PD-1 antibody Tyvyt. Investors cheered the development, betting that Limertinib can become a blockbuster therapy given the high prevalence of the targetted mutation in Asian patient populations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}